Please ensure Javascript is enabled for purposes of website accessibility

Why DexCom Stock Rocketed Higher in April

By George Budwell – May 11, 2020 at 9:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

DexCom's shares have been crushing it of late.

What happened

Medical device company DexCom (DXCM -0.88%) saw its shares gain a stately 31.5% during the month of April, according to data from S&P Global Market Intelligence. The company's shares burst higher last month for two inter-related reasons.

So what

First up, DexCom's stock lost as much as 30% of its value in March in response to the COVID-19 sell-off. Bargain hunters clearly viewed this dip as a once-in-a-lifetime buying opportunity. Underscoring this point, the biotech's shares have now gained an astounding 112% since hitting a two-year low in late March. That's a nearly unheard of type of move for a large-cap stock. 

A wooden spoon pouring sugar on a wooden table around a set of wooden blocks that spell the word diabetes

Image Source: Getty Images.

Secondly, DexCom crushed Wall Street's consensus first-quarter revenue forecast toward the end of April. Thanks to strong demand for its continuous glucose monitoring (CGM) devices, DexCom topped analysts' Q1 revenue estimate by a staggering 13.3%.

While the company couldn't rule out negative impacts from the ongoing COVID-19 pandemic, DexCom has yet to experience any significant headwinds from this outbreak. Not many large-cap healthcare companies can make that claim right now.  

Now what

Is DexCom's stock still a strong buy? That's a hard question to answer. DexCom's stock has repeatedly defied conventional wisdom when it comes to classic valuation metrics. As proof, the company's shares have consistently been valued at over 15 times forward-looking sales.

DexCom's incredible run, however, may be close to hitting a high-water mark after this latest surge. The stock, after all, is now valued at an astronomical 17.3 times 2021 projected sales. That's an exceedingly rich valuation, even for an ultra high-growth company like DexCom. As such, it might be a good idea to wait for a more attractive entry point. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DexCom, Inc. Stock Quote
DexCom, Inc.
$79.64 (-0.88%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.